Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
215.5 USD | +3.16% | +11.02% | -16.72% |
Apr. 29 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- With an enterprise value anticipated at 3.49 times the sales for the current fiscal year, the company turns out to be overvalued.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.72% | 30.42B | B- | ||
-4.06% | 86.13B | A- | ||
+1.97% | 39.82B | A- | ||
+56.59% | 25.23B | A | ||
-14.82% | 15.36B | C | ||
-8.82% | 11.95B | D+ | ||
-16.29% | 11.6B | B- | ||
-41.58% | 11.51B | B | ||
+6.14% | 8.71B | B+ | ||
-7.02% | 8.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIIB Stock
- Ratings Biogen Inc.